 |
 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 March 1997 | Volume 126 Issue 5 | Page 410
Gabapentin is an antiepileptic drug that has diverse complications and side effects, but an extensive review of the literature [1] failed to show stuttering as one of the complications [2, 3].
A 58-year-old woman was recently hospitalized because of an intractable seizure. She had been taking Dilantin (Parke Davis, Morris Plains, New Jersey) as an antiepileptic drug. Gabapentin was administered, the seizures stabilized within a few days, and the patient was discharged.
During a follow-up visit in the outpatient clinic, the patient presented with stuttering. The patient denied any history of stuttering. Gabapentin therapy was discontinued; 4 days later, the patient's stuttering subsided.
We believe that this is the first case report to implicate gabapentin as a potential cause of stuttering.
1. Onslow M. Choosing a treatment procedure for early stuttering: issues and future directions. J Speech Hearing Res. 1992; 35:983-93.
2. Messiha FS. Fluoxentine: adverse effects and drug-drug interactions. J Toxicol Clin Toxicol. 1993; 31:603-30.
3. Watson JB. Improving the effectiveness of stuttering intervention: the journey continues. Folia Phoniatr Logop. 1994; 46:214-22. About Letters
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
LETTER
Stuttering Caused by Gabapentin
TO THE EDITOR:
Author and Article Information
Top
Author & Article Info
References
St. John's Episcopal Hospital, Far Rockaway, NY 11691
References
Top
Author & Article Info
References
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
This article has been cited by other articles:
|
|
 |
|
  S. Gabardi, K. Munz, and C. Ulbricht A Review of Dietary Supplement-Induced Renal Dysfunction Clin. J. Am. Soc. Nephrol., July 1, 2007; 2(4): 757 - 765. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Y. Yeh, D. M. Eisenberg, R. B. Davis, and R. S. Phillips Use of Complementary and Alternative Medicine Among Persons With Diabetes Mellitus: Results of a National Survey Am J Public Health, October 1, 2002; 92(10): 1648 - 1652. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Sekula, J. Havel, and L. J. Otillar Nail Salons Can Be Risky Business Arch Dermatol, March 1, 2002; 138(3): 414 - 415. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Crone, G. Gabriel, and T. N. Wise Non-Herbal Nutritional Supplements--The Next Wave: A Comprehensive Review of Risks and Benefits for the C-L Psychiatrist Psychosomatics, August 1, 2001; 42(4): 285 - 299. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Palomeras, P. Sanz, A. Cano, and P. Fossas Dystonia in a Patient Treated With Propranolol and Gabapentin Arch Neurol, April 1, 2000; 57(4): 570 - 571. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Porter, L. W. Raymond, and G. D. Anastasio Chromium: Friend or Foe? Arch Fam Med, September 1, 1999; 8(5): 386 - 390. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article
